CasLoc logo
All Cases PTAB Litigations UPC Oppositions

The Medicines Company v. Exela Pharma Sciences, LLC

5:14-cv-00058

Overview

Case Number 5:14-cv-00058
Filing Date 2014-04-25
Status Terminated
Termination Date 2018-03-26
Court District Court, W.D. North Carolina (ncwd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 15:1126 Patent Infringement
Jury Demand None

Parties

Defendant

Exela Pharma Sciences, LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

The Medicines Company NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, W.D. North Carolina (ncwd)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (1): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (3 found):
U.S. Courts: 3
U.S. District Court 2011-04-28
3:11-cv-02456

THE MEDICINES COMPANY v. DR. REDDY'S LABORATORIES LTD.

U.S. Family Sibling (["US7582727"])
Status: NJD
U.S. District Court 2010-08-19
1:10-cv-00700

Medicines Company v. Hospira Inc.

Asserted Patent
Status: DED
U.S. District Court 2009-10-08
1:09-cv-00750

Medicines Company v. Hospira Inc.

U.S. Family Sibling (["US7582727"])
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7582727
Pharmaceutical formulations of bivalirudin and processes of making the same
Filed: 2008-07-27
Issued: 2009-09-01
Active (1.7 yrs remaining)
Expires: 2028-07-27
US7598343
Pharmaceutical formulations of bivalirudin and processes of making the same
Filed: 2008-07-27
Issued: 2009-10-06
Active (1.7 yrs remaining)
Expires: 2028-07-27

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

62

Dispositive

1

Granted

22

Denied

5

Pending / Review

33

Motions by Category

Procedural / Extension Motion 20 Claim Construction / Markman Filing 7 Motion to Compel Discovery 19 Motion to Stay 15 Motion to Dismiss 1

Key Dispositive Motions & Rulings

Motion to Dismiss Granted
ORDER granting 94 Joint Motion to Stay. This civil action is stayed until the Federal Circuit issues a mandate in The Medicines Co. v. Hospira, Inc., 14-146...
Entry #96 • 2015-07-15 Document →
Motion to Compel Discovery Denied
ORDER denying 105 Plaintiff's Motion to Lift Stay and Compel Discovery. Signed by Magistrate Judge David S. Cayer on 9/29/16. (smj)
Entry #115 • 2016-09-29 Document →
Motion to Stay Pending / Under Review
REPLY to Response to Motion re 105 MOTION to Lift Stay re 96 Order on Motion to Stay, and Compel Discovery by The Medicines Company. (Thomas, Christopher) (Ente...
Entry #113 • 2016-09-26 Document →
Motion to Compel Discovery Pending / Under Review
DECLARATION of Christopher M. Thomas re 113 Reply to Response to Motion to Lift the July 2015 Stay and Compel Discovery filed by The Medicines Company (Attachme...
Entry #114 • 2016-09-26 Document →
Motion to Stay Pending / Under Review
RESPONSE to Motion re 105 MOTION to Lift Stay re 96 Order on Motion to Stay, and Compel Discovery by Exela Holdings, Inc., Exela Pharma Sciences, LLC, Exela Pha...
Entry #111 • 2016-09-16 Document →
Motion to Stay Pending / Under Review
DECLARATON in Opposition re 105 MOTION to Lift Stay re 96 Order on Motion to Stay, and Compel Discovery Declaration of Satish C. Chintapalli by Exela Holdings, ...
Entry #112 • 2016-09-16 Document →

Docket Entries

(132 total)
Pleading / Complaint

COMPLAINT against All Defendants ( Filing fee $ 400 receipt number 0419-2293311), filed by The Medicines Company. (Attachments: # 1 Exhibit A-US Patent 7,582,727, # 2 Exhibit B-US Patent 7,598,343)(Dubis, Melanie) (Entered: 04/25/2014)

Entry #1 • 2014-04-25
1

NOTICE of Appearance by Melanie Black Dubis on behalf of The Medicines Company (Dubis, Melanie) (Entered: 04/25/2014)

Entry #2 • 2014-04-25
1

Corporate Disclosure Statement by The Medicines Company (Dubis, Melanie) (Entered: 04/25/2014)

Entry #3 • 2014-04-25
1
Pleading / Complaint

Attachment by The Medicines Company. Attachment to 1 Complaint Civil Cover Sheet (Dubis, Melanie) (Entered: 04/25/2014)

Entry #4 • 2014-04-25
1

WRONG EVENT SELECTED - Image Deleted - Motion/Pro Hac Vice by The Medicines Company (Robert Colletti) (Dubis, Melanie) Modified on 4/28/2014 to change to motion filed (smj). Regenerated NEF. Modified on 4/29/2014 (cbb) to delete image. Refiled as Dcmt 9. Regenerated NEF. (Entered: 04/25/2014)

Entry #5 • 2014-04-25
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc